Bryant Lum, MD
Ophthalmology · Ventura, CANPI 1104860691
Payments from drug & device makers
Across 369 payments — averaging $429.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$94K
- Aerie Pharmaceuticals, Inc.$22K
- Glaukos Corporation$14K
- Rxsight Inc$9K
- Bausch Health US, LLC$6K
- Sight Sciences, Inc.$4K
- plus $10K from 30 others
What the payments were for
- Consulting fees$12,07026%
- Speaking & faculty fees$17,92139%
- Travel & lodging$2,5966%
- Food & beverage$13,16129%
- Gifts$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $93,550 |
| Aerie Pharmaceuticals, Inc. | 43 | $21,598 |
| Glaukos Corporation | 20 | $14,142 |
| Rxsight Inc | 13 | $8,662 |
| Bausch Health US, LLC | 4 | $6,420 |
| Sight Sciences, Inc. | 29 | $3,866 |
| Alcon Research LLC | 1 | $2,450 |
| Alcon | 49 | $2,095 |
| Tarsus Pharmaceuticals, Inc. | 5 | $1,257 |
| Ivantis, Inc | 8 | $732 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $606 |
| Notal Vision, Inc. | 1 | $445 |
| NEW World Medical,inc. | 6 | $443 |
| Ellexiscience | 1 | $324 |
| Biotissue Holdings Inc. | 13 | $235 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $234 |
| Dompe US, Inc. | 7 | $190 |
| Harrow Eye, LLC | 4 | $183 |
| Bausch & Lomb Americas Inc. | 9 | $177 |
| Lensar, Inc. | 1 | $159 |
| Akorn, Inc. | 4 | $89 |
| Oyster Point Pharma, Inc. | 2 | $86 |
| Sun Pharmaceutical Industries Inc. | 4 | $84 |
| Eyepoint US, Inc. | 3 | $66 |
| Maculogix, Inc. | 3 | $65 |
| Thea Pharma Inc. | 3 | $61 |
| Amgen | 3 | $60 |
| Eyevance Pharmaceuticals LLC | 2 | $42 |
| Kala Pharmaceuticals, Inc. | 2 | $39 |
| Optos, Inc. | 2 | $39 |
| Akorn Operating Company LLC | 2 | $33 |
| Novartis | 2 | $28 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$21,099
- Rocklatan$20,980
- Travoprost Intraocular Implant - iDose$5,504
- iDose$2,059
- XEN GLAUCOMA TREATMENT SYSTEM$842
- Constellation$693
- iStent Infinite$469
- Hydrus Microstent$411
- Hydrus$312
- OMNI(R) SURGICAL SYSTEM (US)$279
- RXSIGHT CONTACT LENS$274
- RXSIGHT INJECTOR CARTRIDGE$274
- RXSIGHT INJECTOR HANDPIECE$274
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$274
- Kahook Dual Blade$251
- Streamline Surgical System$251
- Ahmed Glaucoma Valve$251
- iDoseTR$162
- LENSAR LASER SYSTEM$159
- LIGHT ADJUSTABLE LENS (LAL)$143
How this compares
$158,543 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $562,822 |
| LumiganBimatoprost | 323 | $130,435 |
| RestasisCyclosporine | 129 | $129,734 |
| RocklatanNetarsudil Mesylat/Latanoprost | 196 | $95,210 |
| RhopressaNetarsudil Mesylate | 100 | $51,881 |
| Cyclosporine | 59 | $39,370 |
| XiidraLifitegrast | 32 | $35,382 |
| CombiganBrimonidine Tartrate/Timolol | 116 | $33,537 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 162 | $24,970 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 64 | $21,125 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 106 | $20,701 |
| VyzultaLatanoprostene Bunod | 39 | $13,784 |
| MieboPerfluorohexyloctane/Pf | 18 | $13,501 |
| Brimonidine Tartrate | 58 | $9,063 |
| Travoprost | 84 | $8,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $190 | $562,82212 claims |
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $93,550 | $300,751588 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $21,598 | $147,091296 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $177 | $62,66689 claims |
| AlconSimbrinza | $2,095 | $21,12564 claims |
| Akorn, Inc.Zioptan, Betimol | $89 | $11,99439 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $606 | $7,34624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Ventura
- Aaron NagielVentura$1.1M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.